Lineage Cell Therapeutics (LCTX) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
16 Nov, 2026Platform and pipeline
AlloSCOPE uses pluripotent stem cell expansion and guided differentiation to produce 200+ cell types, targeting scalable, consistent, off-the-shelf therapies.
5D uses microcarriers as a 2D surface in a 3D bioreactor, aiming for controlled differentiation with less handling and lower aseptic risk.
GMP-scale production was demonstrated using two cell lines and cell types; product vial capability is 1M–20M, with automated fill-finish needed for the upper range.
Pipeline includes 7 cell types in development, 2 active clinical trials, and ~375 issued and pending patents.
Cash, cash equivalents and marketable securities totaled $50.8M as of June 30, 2026.
OpRegen
Roche and Genentech lead clinical development and commercialization under a 2021 license; terms include $50M upfront, a $5M milestone received in Dec 2025, up to $615M in additional milestones and double-digit royalties.
Phase 1/2a Cohort 4 showed mean visual acuity gains of +6.2 ETDRS letters at 36 months; the extensive-bleb subgroup (n=5) gained +9.0 letters.
All 5 patients with extensive bleb coverage showed retinal structural improvement; improvement was observed within 3 months and only within lesions covered by the bleb.
The Genentech-sponsored GAlette Phase 2a study evaluates delivery, safety and preliminary activity; enrollment is up to 60 across 17 U.S. and Israel sites.
The program has FDA Fast Track and RMAT designations and potential application in other retinal diseases, including Stargardt disease.
OPC1
More than 30 patients have been treated; cervical and thoracic studies reported no unexpected serious adverse events related to transplantation, with follow-up of at least 8 and 14 years, respectively.
In cervical Cohort 2, 4 of 6 subjects gained at least 2 motor levels on one side at 12 months and 5 of 6 at 24 months; no enrolled patients had worsening neurological function.
Among 25 treated subjects, no serious adverse events were related to OPC1 cells; safety data spans 2–5 years.
At 24 months, 24 of 25 patients had serial MRI scans showing no lesion cavity, based on 22 available scans.
The DOSED study evaluates a new delivery device in 6–10 patients, including 3–5 subacute and 3–5 chronic injuries; preparations are underway for a larger controlled trial.
Latest events from Lineage Cell Therapeutics
- HUNT1 joins the pipeline as warrant gains lift Q3 earnings and runway extends into Q2 2028.LCTX
Q3 2026 - Pipeline expansion and clinical execution anchor the 2023 priorities.LCTX
Q4 2022 - Returned to profitability in Q2 2026 with strong clinical progress and cash runway into Q3 2028.LCTX
Q2 2026 - COR1 advances scalable, high-quality cell therapy for corneal disease with animal data expected soon.LCTX
Study update - OpRegen's cell therapy for dry AMD shows durable vision gains and global expansion with Roche.LCTX
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Lead cell therapy programs in dry AMD and spinal cord injury show durable clinical benefits.LCTX
Corporate presentation - Q1 2026 revenue up 15% to $1.7M, $53.4M cash, pipeline and manufacturing milestones achieved.LCTX
Q1 2026 - Votes will be held on director elections, auditor ratification, and executive pay approval.LCTX
Proxy filing - Durable clinical gains, improved financials, and manufacturing strength drive program momentum.LCTX
Q4 2024